reported that the ratio of circulating exhausted-phenotype-CD8 T-cell reactivation to pretreatment total BTS correlated with clinical outcome, based on peripheral blood immune profiling analysis of patients with melanoma before and after PD-1 inhibitor treatment. This evidence concerns the gene CD8A and melanoma.